Liquid biopsy can quantify and qualify cell-free (cfDNA) and tumour-derived (ctDNA) DNA fragments in the bloodstream. CfDNA quantification and mutation analysis can be applied to diagnosis, follow-up and therapeutic management as novel oncologic biomarkers. However, some tumor-types release a low amount of DNA into the bloodstream, hampering diagnosis through standard liquid biopsy procedures. Several tumors, as such as brain, kidney, prostate, and thyroid cancer, are in direct contact with other body fluids and may be alternative sources for cfDNA and ctDNA. Non-blood sources of cfDNA/ctDNA useful as novel oncologic biomarkers include cerebrospinal fluids, urine, sputum, saliva, pleural effusion, stool and seminal fluid. Seminal plasma cfDNA, which can be analyzed with cost-effective procedures, may provide powerful information capable to revolutionize prostate cancer (PCa) patient diagnosis and management. In the near future, cfDNA analysis from non-blood biological liquids will become routine clinical practice for cancer patient diagnosis and management.

Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology / Ponti, G.; Manfredini, M.; Tomasi, A.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 141:(2019), pp. 36-42. [10.1016/j.critrevonc.2019.06.005]

Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology

Ponti G.
Writing – Original Draft Preparation
;
Manfredini M.
Membro del Collaboration Group
;
Tomasi A.
Membro del Collaboration Group
2019

Abstract

Liquid biopsy can quantify and qualify cell-free (cfDNA) and tumour-derived (ctDNA) DNA fragments in the bloodstream. CfDNA quantification and mutation analysis can be applied to diagnosis, follow-up and therapeutic management as novel oncologic biomarkers. However, some tumor-types release a low amount of DNA into the bloodstream, hampering diagnosis through standard liquid biopsy procedures. Several tumors, as such as brain, kidney, prostate, and thyroid cancer, are in direct contact with other body fluids and may be alternative sources for cfDNA and ctDNA. Non-blood sources of cfDNA/ctDNA useful as novel oncologic biomarkers include cerebrospinal fluids, urine, sputum, saliva, pleural effusion, stool and seminal fluid. Seminal plasma cfDNA, which can be analyzed with cost-effective procedures, may provide powerful information capable to revolutionize prostate cancer (PCa) patient diagnosis and management. In the near future, cfDNA analysis from non-blood biological liquids will become routine clinical practice for cancer patient diagnosis and management.
2019
7-giu-2019
141
36
42
Non-blood sources of cell-free DNA for cancer molecular profiling in clinical pathology and oncology / Ponti, G.; Manfredini, M.; Tomasi, A.. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 141:(2019), pp. 36-42. [10.1016/j.critrevonc.2019.06.005]
Ponti, G.; Manfredini, M.; Tomasi, A.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842818303469-main.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 275.17 kB
Formato Adobe PDF
275.17 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
POST_PRINT_j.critrevonc.2019.06.005.pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 706.54 kB
Formato Adobe PDF
706.54 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1179222
Citazioni
  • ???jsp.display-item.citation.pmc??? 31
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 42
social impact